Making way for suppressing the FGF19/FGFR4 axis in cancer

Nestor Prieto-Dominguez, Austin Y. Shull, Yong Teng

Research output: Contribution to journalReview articlepeer-review

13 Scopus citations


FGF19 is a noncanonical FGF ligand that can control a broad spectrum of physiological responses, which include bile acid homeostasis, liver metabolism and glucose uptake. Many of these responses are mediated by FGF19 binding to its FGFR4/β-klotho receptor complex and controlling activation of an array of intracellular signaling events. Overactivation of the FGF19/FGFR4 axis has been implicated in tumorigenic formation, progression and metastasis, and inhibitors of this axis have recently been developed for single agent use or in combination with other anticancer drugs. Considering the critical role of this receptor complex in cancer, this review focuses on recent developments and applications of FGF19/FGFR4-targeted therapeutics.

Original languageEnglish (US)
Pages (from-to)2457-2470
Number of pages14
JournalFuture Medicinal Chemistry
Issue number20
StatePublished - Oct 2018


  • FGF19
  • FGFR4
  • anticancer
  • inhibitors
  • oncogenic role
  • signaling transduction
  • treatment regimens

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'Making way for suppressing the FGF19/FGFR4 axis in cancer'. Together they form a unique fingerprint.

Cite this